Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ

Clinicians should be aware of near-fivefold raised risk for osteonecrosis of the jaw (ONJ) if zoledronic acid is used to prevent cancer bone metastases, warn researchers.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news